GHRP-6: The Original GH-Releasing Peptide, Hunger Included

At a Glance

GHRP-6 is the molecule that started this field. In 1984 Bowers and colleagues described a synthetic hexapeptide that released growth hormone in rats, monkeys, lambs and calves without touching LH, FSH, TSH or prolactin in the same assays, and argued it behaved like a hypophysiotropic hormone whose natural counterpart had not yet been found (Bowers 1984). That prediction was right. Thirteen years later the receptor’s natural ligand was identified as ghrelin.

The honest verdict: GHRP-6 does two things reliably in humans. It produces a large, short growth hormone pulse, and it makes people hungry. Everything else attached to it, from tissue healing to cardioprotection, rests on animal and cell work that is scientifically interesting and clinically untested.

Its appetite effect is the main practical difference from the rest of the class. For someone who needs to eat more, that is the feature. For someone trying to lose fat, it is the reason to choose a different molecule.

How it works

GHRP-6 activates GHS-R1a, the G-protein-coupled receptor also used by ghrelin. Activation in the pituitary and hypothalamus increases GH release through a pathway separate from GHRH, which is why the two are synergistic: GHRP alone, GHRH alone, and the combination produce progressively larger pulses, with the combination exceeding the sum of the parts (Bowers 1990).

Three mechanistic points matter:

• The pulse is preserved. During a 24-hour infusion of GHRP at 1 mcg/kg/h in eight normal men, GH secretion rose eightfold over saline and stayed pulsatile, with more pulses and higher pulse amplitude. The same study showed specific blunting of the response to a later GHRP bolus, the clearest human demonstration of receptor-level adaptation in this class (Huhn 1993).
• Appetite comes with the receptor. Ghrelin signalling drives meal initiation. Direct food-intake measurements exist for GHRP-2 rather than GHRP-6 (Laferrère 2006), and GHRP-6 is consistently described as the stronger appetite stimulus of the two.
• There is a second receptor. GHRPs of this family also bind CD36, a scavenger receptor expressed in cardiomyocytes and microvascular endothelium, and CD36 activation produces cardiovascular effects that do not require GH at all (Bodart 2002). This is the mechanistic basis for the cytoprotection literature, which runs through PI3K/Akt survival signalling (Berlanga-Acosta 2017).

What the evidence shows

Human data

GH release and route comparisons. The founding human study showed dose-related GH release at 0.1, 0.3 and 1.0 mcg/kg intravenously, with peak GH of 68.7 mcg/L at the top dose against 1.2 mcg/L on placebo, and no adverse clinical or laboratory findings (Bowers 1990). Oral administration works at roughly 300 times the intravenous dose: in 13 children with short stature, oral GHRP-6 at 300 mcg/kg raised GH from 1.1 to 18.8 mcg/L at 60 minutes, comparable to a maximally effective intravenous dose of GHRH (Bellone 1995).

Pharmacokinetics. Nine healthy men received single intravenous boluses of 100, 200 and 400 mcg/kg. Disposition fitted a two-compartment model, with a distribution half-life of 7.6 ± 1.9 minutes and an elimination half-life of 2.5 ± 1.1 hours (Cabrales 2013). Note the scale: these are far above the microgram doses used in practice, and they were tolerated in a monitored setting.

Desensitisation. The 24-hour infusion study is the key piece. GH secretion stayed elevated and pulsatile throughout, but the response to a later GHRP bolus was specifically attenuated while the GHRH response was not (Huhn 1993). Receptor-level adaptation is real, partial and fairly quick.

Hormonal selectivity. Comparative work in man shows this peptide family raises prolactin, ACTH and cortisol alongside GH, with GHRP-6 the least selective of the commonly used members (Arvat 1997).

Animal and cell data, clearly labelled as such

• Myocardial infarction (pigs). Female Cuban Creole pigs underwent one hour of circumflex occlusion followed by 72 hours of reperfusion. GHRP-6 at 400 mcg/kg reduced infarct size and the proportion of animals with pathological Q waves compared with saline (Berlanga 2007).
• Cytoprotection, broadly. A review of the GHRP class documents prosurvival signalling through CD36 and GHS-R1a across cardiac, hepatic, renal and skin injury models, and makes the point that this pharmacology never reached a clinical niche (Berlanga-Acosta 2017).
• Regulatory-grade toxicology. A GHRP-6-based product, CIGB-500, was given intravenously to beagles daily for 28 days at 300, 1,000 and 2,000 mcg/kg/day. Transient hypersalivation, reduced heart rate and head erythema appeared at the two higher doses and were judged non-adverse (Castro 2025). This is the most formal safety data set the molecule has, and it is in dogs.

What is missing

No human trial of body composition, strength, wound healing, cardiac outcomes or any patient-reported endpoint. The narrative review of this class places GHRP-6 in its lowest evidence tiers for performance and recomposition claims (Dominikowski 2026).

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Titration as it is actually done. Start with one 100 mcg injection, usually before bed, for the first week. The hunger response declares itself within 20 to 30 minutes, so the first dose tells most people whether they will tolerate the compound at all. Further daily injections get added after that, with food kept away from the injection window because a carbohydrate or protein load blunts the GH response.

On and off cycle. Blocks of 8 to 12 weeks with around four weeks off are standard, often rotating with ipamorelin to limit the appetite burden. Unlike most cycling folklore, this one has a human rationale: the specific blunting of the GHRP response during continuous exposure (Huhn 1993).

Technique, reconstitution and storage belong in the peptide injection guide. Multi-compound cycle structure is in peptide cycling protocols.

What people report: what works and what doesn’t

Sources: the aggregated community data sets (Peptide Protocol Wiki, 100 reports; Peptide DB), the protocol and adverse-effect patterns in the peer-reviewed review of this class (Dominikowski 2026), and the published human pharmacology above. Patterns, not proof.

Reported to work

• Intense hunger 20 to 30 minutes after an injection. The most consistent report about GHRP-6 anywhere, and the main reason people either choose it or avoid it.
• Easier eating in a calorie surplus, and for underweight people, easier weight gain. The mechanism supports it, and the GHRP-2 food-intake trials make the class effect concrete.
• Deeper sleep on a pre-bed dose, described widely, never tested against placebo for this peptide.
• Fluid retention within the first two weeks, usually read as a GH effect rather than new tissue.

Mixed or unclear

• Recovery and connective-tissue comfort. Reported, mechanistically plausible from the cytoprotection work, but that work is in animals and the reports almost always involve a stack.
• Whether the hunger fades. Some describe tolerance after a few weeks, others never get it.
• Flushing and a warm sensation after injection. Common, usually harmless, variable between people and batches.

Reported not to work, or disappointing

• Fat loss. GHRP-6 is the wrong tool and the reports say so. Appetite stimulation on this scale defeats most deficits.
• Muscle gain on GHRP-6 alone. The familiar disappointment across GH secretagogues. Physiological pulsatile GH is not an anabolic steroid.
• Side effects people stop for: hunger they cannot control, morning puffiness, wrist and hand tingling, lethargy, and in people who test, mildly raised prolactin or cortisol. Those laboratory patterns are recognised class effects rather than evidence of pituitary disease (Dominikowski 2026).
• The cytoprotection story in practice. People who try GHRP-6 for healing rather than GH generally report it underwhelming next to BPC-157 or TB-500, which is unsurprising when the supporting cardiac data are porcine.

What a properly designed trial would need to show: a randomised, placebo-controlled trial of at least 12 weeks with imaging-based body composition, strength and glucose endpoints, or, for the cytoprotection claim, a human trial with an actual tissue-injury outcome.

Safety and side effects

Reported in humans. Facial flushing, warmth, sweating, transient drowsiness, hunger and injection-site reactions. Prolactin, ACTH and cortisol rise modestly at GH-releasing doses (Arvat 1997). Single intravenous doses up to 400 mcg/kg were tolerated in a monitored pharmacokinetic study (Cabrales 2013).

Predictable from GH physiology. Fluid retention, paraesthesia, arthralgia and reduced insulin sensitivity. FDA’s own summary for GHRP-6 cites limited safety data and concerns about effects on cortisol and blood glucose through reduced insulin sensitivity. Anyone with prediabetes or diabetes needs glucose and HbA1c followed.

IGF-1 and long-term risk. As with every GH secretagogue, the intended effect is sustained IGF-1 elevation, and the epidemiological association between higher IGF-1 and prostate and premenopausal breast cancer is the unresolved background risk (Renehan 2004). Active malignancy should be treated as a contraindication.

Unknowns. No human exposure beyond short research protocols. No data in pregnancy or lactation. No long-term data. Interactions with insulin, glucocorticoids (which blunt GH release) and GLP-1 agonists (opposing appetite effects) are unstudied.

Product quality. GHRP-6 is cheap and widely counterfeited. Analyses of seized material have found mislabelled contents, unassigned fusion proteins and degradation products, and 12% of 1,190 products seized at the Swiss border were labelled as peptide hormones or growth factors with recurring quality failures (Weber 2017). See peptide sourcing.

Legal and regulatory status

United States. No approved product. On FDA’s 503A bulk drug substance list (updated 14 May 2026) GHRP-6 is in category 3, nominated without adequate supporting information, so the interim enforcement policy covering category 1 substances does not apply to it. Under the 503B outsourcing-facility policy it is in category 2 (significant safety risks), where FDA cites possible immunogenicity for certain routes, limited safety data and the cortisol and glucose concerns above. Context in the FDA 2026 compounding update.

European Union and Germany. No EMA or BfArM authorisation. GHRP-6 and GHRP-6-Gly are named in the annex to Germany’s Anti-Doping Act (AntiDopG) among the growth hormone releasing peptides. Under § 2(3) it is an offence to acquire, possess or import more than a “non-small quantity” for the purpose of doping in sport, and the quantity regulation (DmMV, in force 16 March 2023) sets that threshold at 1.5 mg for the GHRP group. A single 5 mg vial is more than three times that quantity, which is worth knowing even though the offence requires the doping purpose.

Cuba. A GHRP-6-based product (CIGB-500) has been taken through preclinical and regulatory toxicology for cardiac indications (Castro 2025). That programme creates no marketing authorisation in the US or EU.

Sport. Prohibited at all times under section S2 of the WADA list, by class rather than by name. Urinary metabolites of GHRP-6 are detectable after nasal and injected administration, and testing for this peptide family now extends to dried blood spots. See peptides and anti-doping rules.

How GHRP-6 fits

The practical hierarchy is simple. If hunger is wanted, GHRP-6. If a GH pulse is wanted with the least hormonal noise, ipamorelin. If someone will not inject, the oral ghrelin-receptor agonist MK-677 covers similar ground with a more pronounced effect on insulin sensitivity. If the real goal is visceral fat with trial evidence attached, tesamorelin is the only compound in this area with phase 3 data and an approval.

What makes GHRP-6 historically important is that it proved an entire receptor system existed before anyone had found its natural ligand. What makes it clinically marginal today is that nobody ever ran the trial.

Related Articles

• GHRP-2 (Pralmorelin): Potent GH Release, Thin Outcome Data — the better-documented sibling, with a diagnostic approval in Japan.
• Ipamorelin: A Physician’s Guide — the selective option at the same receptor.
• Ibutamoren (MK-677): A Physician’s Guide — the oral ghrelin-receptor agonist.
• Peptides for Muscle Growth: What the Evidence Actually Supports — the comparative picture.
• Peptide Therapy for Athletes: What’s Banned Under WADA Rules in 2026 — class-based prohibition.